Pine Labs Limited (PINELABS)
Investor Presentation
Investor Presentation - Q2 FY27
- Revenue ₹806 Cr +24% YoY; Adjusted EBITDA ₹155 Cr +27% YoY; PAT ₹39 Cr +546% YoY
- Revenue growth driven by broad-based momentum across platforms; Mid-market DCPs up 49% YoY
- Adjusted EBITDA margin steady at ~19%; investments in tech, brand, and talent ongoing
- Operating cash flow doubled YoY to ₹350 Cr; net working capital at 14%, within guidance
- UPI transactions 70%+ of DCP mix; monthly UPI GTV ~₹20k Cr, expected to reach ₹33-34k Cr in FY28
- New product launches include Employee Benefits Card, Digital Mobility Card, Stablecoin prepaid card
- International business growing ~40% YoY; multi-year contract renewals and regional expansion
- Management confident in sustaining growth and margin trajectory through H2 FY27
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 PINELABS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add PINELABS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Pine Labs Limited
Important.
The summary above is generated automatically from Pine Labs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.